Trial Outcomes & Findings for A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma (NCT NCT01970358)

NCT ID: NCT01970358

Last Updated: 2025-12-29

Results Overview

Number of participants experiencing any of the following: * Grade-3 or -4 toxicity that is definitely, probably, or possibly related to the administration of vaccine * Grade-3 or -4 abnormal laboratory value that is definitely, probably, or possibly related to the administration of vaccine if it persists for more than 7 days, requires hospitalization, or medical intervention * Any grade-3 or grade- 4 toxicity that is considered, in the opinion of the investigator, to be dose-limiting * Any death related to study treatment A minimum of 3 vaccinations and absence of DLTs are required for a patient to complete the 7-week DLT observation period successfully.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

15 participants

Primary outcome timeframe

7 weeks from first study drug administration

Results posted on

2025-12-29

Participant Flow

Dates of recruitment: April 2014 through July 2016.

Participant consent/screening was conducted in two stages. Participants first had surgery with the intention to remove all melanoma. After confirmation of complete tumor resection by pathologic review and determination of adequacy of DNA and RNA from tumor tissue for sequencing, participants were reconsented for generation of the vaccine. Participants with tumors that were not completely resected and/or that provided inadequate DNA and/or RNA for sequencing were removed from the trial.

Participant milestones

Participant milestones
Measure	Personalized NeoAntigen Cancer Vaccine \- NeoVax (peptides + poly-ICLC) Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 134 Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 134
Overall Study STARTED	15
Overall Study COMPLETED	8
Overall Study NOT COMPLETED	7

Reasons for withdrawal

Reasons for withdrawal
Measure	Personalized NeoAntigen Cancer Vaccine \- NeoVax (peptides + poly-ICLC) Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 134 Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 134
Overall Study Unable to make NeoVax or NeoVax not viable	3
Overall Study Ineligible at time of second consent	4

Baseline Characteristics

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Personalized NeoAntigen Cancer Vaccine n=15 Participants \- NeoVax (peptides + poly-ICLC) Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 134 Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 134 Poly-ICLC Peptides
Age, Continuous	61 years n=174 Participants
Sex: Female, Male Female	7 Participants n=174 Participants
Sex: Female, Male Male	8 Participants n=174 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=174 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	15 Participants n=174 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=174 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=174 Participants
Race (NIH/OMB) Asian	0 Participants n=174 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=174 Participants
Race (NIH/OMB) Black or African American	0 Participants n=174 Participants
Race (NIH/OMB) White	15 Participants n=174 Participants
Race (NIH/OMB) More than one race	0 Participants n=174 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=174 Participants
Melanoma AJCC Stage IIIB	3 Participants n=174 Participants
Melanoma AJCC Stage IIIC	7 Participants n=174 Participants
Melanoma AJCC Stage IV M1a	3 Participants n=174 Participants
Melanoma AJCC Stage IV M1b	2 Participants n=174 Participants

PRIMARY outcome

Timeframe: 7 weeks from first study drug administration

Population: Number of participants receiving NeoVax.

Outcome measures

Outcome measures
Measure	Personalized NeoAntigen Cancer Vaccine n=8 Participants \- NeoVax (peptides + poly-ICLC) Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 134 Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 134
Number of Participants Experiencing Clinical and/or Laboratory Dose-limiting Toxicities	0 Participants

PRIMARY outcome

Timeframe: 12 weeks

Population: Number of participants with complete resection and adequate DNA/RNA for sequencing.

The proportion of participants for whom sequencing and analysis leads to identification of at least 10 actionable peptides to initiate vaccine production. The primary assessment of feasibility will be based on on all participants enrolled with a confirmation of completely resected tumor and with adequate DNA and RNA for sequencing. NeoVax would be feasible if no more than 50% of participants have fewer than 10 actionable peptides or have NeoVax available more than 12 weeks after confirmation of complete resection. If 4 or fewer of the first 15 participants have insufficient vaccine or first dose delays of more than 12 weeks, then the upper bound of the one-sided 90% exact confidence interval will be less than 50% and we will consider the process feasible. If 5 or more of the first 15 patients have insufficient or delayed vaccine, we will consider the vaccine not feasible. The planned vaccination regimen will be administered even if the feasibility endpoints are not met.

Outcome measures

Outcome measures
Measure	Personalized NeoAntigen Cancer Vaccine n=11 Participants \- NeoVax (peptides + poly-ICLC) Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 134 Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 134
Proportion of Participants for Whom Sequencing and Analysis Leads to Identification of at Least 10 Actionable Peptides to Initiate Vaccine Production	0.73 Proportion of participants Interval 0.44 to 0.92

SECONDARY outcome

Timeframe: 16 weeks

Population: Participants receiving NeoVax.

The induction of IFN-γ T-cell response will be based on ELISPOT assessments taken prior to vaccine administration and at week 16. The proportion of participants who achieve more than 55 SFU/10\*\*6 PBMC or 3 times their baseline level will be presented with a 90% exact binomial confidence interval. Based on a cohort of size 15, the confidence interval will be no wider than 0.46.

Outcome measures

Outcome measures
Measure	Personalized NeoAntigen Cancer Vaccine n=8 Participants \- NeoVax (peptides + poly-ICLC) Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 134 Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 134
Proportion of Participants With Specific Cellular Immune Responses Following Administration of NeoVax	1.00 Proportion of participants Interval 0.69 to 1.0

SECONDARY outcome

Timeframe: 2 Years

Population: Participants who received NeoVax.

The proportion of participants alive, without disease progression at two years after resection estimated using the method of Kaplan-Meier. The endpoint is calculated as the time between pathological confirmation of complete resection and the first of disease recurrence or death. The follow-up of participants disease-free at the time of study reporting is censored at the time of the last study visit. Participants disease-free at the time of their last assessment and who have either been lost to follow-up or withdrawn consent will have their follow-up censored at the time of the last study assessment.

Outcome measures

Outcome measures
Measure	Personalized NeoAntigen Cancer Vaccine n=8 Participants \- NeoVax (peptides + poly-ICLC) Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 134 Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 134
Proportion of Participants Alive Without Progression at Two Years After Surgery Following Administration of NeoVax	0.75 proportion of participants Interval 0.4 to 0.91

Adverse Events

Personalized NeoAntigen Cancer Vaccine

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Personalized NeoAntigen Cancer Vaccine n=8 participants at risk \- NeoVax (peptides + poly-ICLC) Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 134 Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 134
General disorders Fatigue	62.5% 5/8 • Number of events 5 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
General disorders Fever	37.5% 3/8 • Number of events 3 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
General disorders Flu like symptoms	50.0% 4/8 • Number of events 10 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
General disorders Injection site reaction	100.0% 8/8 • Number of events 18 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
General disorders Pain	25.0% 2/8 • Number of events 2 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Immune system disorders Allergic reaction	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Infections and infestations Upper respiratory infection	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Injury, poisoning and procedural complications Bruising	37.5% 3/8 • Number of events 4 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Investigations Alanine aminotransferase increased	25.0% 2/8 • Number of events 4 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Investigations Alkaline phosphatase increased	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Investigations Aspartate aminotransferase increased	37.5% 3/8 • Number of events 5 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Investigations Blood bilirubin increased	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Investigations Neutrophil count decreased	37.5% 3/8 • Number of events 3 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Investigations White blood cell decreased	12.5% 1/8 • Number of events 3 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Metabolism and nutrition disorders Dehydration	12.5% 1/8 • Number of events 2 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Metabolism and nutrition disorders Hyperglycemia	12.5% 1/8 • Number of events 2 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Metabolism and nutrition disorders Hypoalbuminemia	37.5% 3/8 • Number of events 4 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Metabolism and nutrition disorders Hypokalemia	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Metabolism and nutrition disorders Hyponatremia	25.0% 2/8 • Number of events 4 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Musculoskeletal and connective tissue disorders Arthralgia	37.5% 3/8 • Number of events 4 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Musculoskeletal and connective tissue disorders Arthritis	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Blood and lymphatic system disorders Anemia	25.0% 2/8 • Number of events 3 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Cardiac disorders Sinus bradycardia	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Cardiac disorders Sinus tachycardia	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Eye disorders Blurred vision	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Eye disorders Watering eyes	12.5% 1/8 • Number of events 2 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Gastrointestinal disorders Diarrhea	25.0% 2/8 • Number of events 2 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Gastrointestinal disorders Dyspepsia	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Musculoskeletal and connective tissue disorders Knee Gout	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Nervous system disorders Dizziness	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Nervous system disorders Dysgeusia	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Nervous system disorders Headache	62.5% 5/8 • Number of events 6 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Psychiatric disorders Insomnia	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Renal and urinary disorders Chronic kidney disease	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Reproductive system and breast disorders Breast pain	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Respiratory, thoracic and mediastinal disorders Cough	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Respiratory, thoracic and mediastinal disorders Dyspnea	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Skin and subcutaneous tissue disorders Dry skin	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Skin and subcutaneous tissue disorders Pruritus	25.0% 2/8 • Number of events 2 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Skin and subcutaneous tissue disorders Rash maculo-papular	37.5% 3/8 • Number of events 6 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Skin and subcutaneous tissue disorders Wart-Like Lesion	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Vascular disorders Hot flashes	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.
Vascular disorders Hypertension	12.5% 1/8 • Number of events 1 • Total of 2 years after treatment initiation. Adverse events assessments every 3 months at re-staging follow-up visits (+/- 1 week) to continue until initiation of a new therapy for recurrent disease, withdrawal of consent, or death, whichever occurs first. All participants who receive one or more doses of NeoVax are included in the safety analysis.

Additional Information

Patrick Ott, MD PhD

Dana-Farber Cancer Institute

Phone: 6176325990

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place